Announced Thu, 15 Oct, 2026 · 18:03 IST

Routine compliance filing under Regulation 74(5) for Q2 FY27

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹24.25

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+4.0% vs market

Pharmaceuticals peers, median of 173sector+0.0%+4.7% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+0.7+4.0+0.0+4.7

Next day

+4.7-1.0+5.7-1.2+5.9

+4.7-3.6+8.3-3.0+7.7

—-4.5—-3.9—

—-6.8—-5.0—

—-6.4—-3.9—

+6.7pendingpending-0.9+7.6

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brawn Biotech has submitted a quarterly certificate from its registrar RCMC Share Registry under SEBI Regulation 74(5). The certificate confirms that share dematerialisation requests received from depository participants during the quarter ended 30 September 2026 were properly processed, certificates were mutilated and cancelled, and depository names were updated in the register of members within 15 days. This is a standard procedural filing with no business or financial implications.

Likely market impact

Routine regulatory compliance. No impact on shareholders, operations, or stock price.